These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 26774017)

  • 21. An overview of new GLP-1 receptor agonists for type 2 diabetes.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Investig Drugs; 2016; 25(2):145-58. PubMed ID: 26587691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists.
    Mabilleau G; Pereira M; Chenu C
    J Endocrinol; 2018 Jan; 236(1):R29-R42. PubMed ID: 28855317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high-dose GLP-1 receptor agonists and GLP-1 receptor-based co-agonists.
    Goldenberg RM; Gilbert JD; Manjoo P; Pedersen SD; Woo VC; Lovshin JA
    Obes Rev; 2024 Mar; 25(3):e13663. PubMed ID: 37968541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
    Lim S; Kim KM; Nauck MA
    Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis.
    Geloneze B; de Lima-Júnior JC; Velloso LA
    Drugs; 2017 Apr; 77(5):493-503. PubMed ID: 28233273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GLP-1 receptor agonists and cardiovascular outcome trials: An update.
    Andrikou E; Tsioufis C; Andrikou I; Leontsinis I; Tousoulis D; Papanas N
    Hellenic J Cardiol; 2019; 60(6):347-351. PubMed ID: 30528435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GLP-1 receptor agonists in NAFLD.
    Petit JM; Vergès B
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S28-2S33. PubMed ID: 28431668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features.
    Lyseng-Williamson KA
    Clin Drug Investig; 2019 Aug; 39(8):805-819. PubMed ID: 31317516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of GLP-1 receptor agonists for type 2 diabetes treatment intensification after basal insulin failure.
    Joubert M; Reznik Y
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S34-2S38. PubMed ID: 28431670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon-like peptide-1 receptor mediated control of cardiac energy metabolism.
    Al Batran R; Almutairi M; Ussher JR
    Peptides; 2018 Feb; 100():94-100. PubMed ID: 29412838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of GLP-1 Analogs in the Management of Diabetes and its Secondary Complication.
    Sivakumar PM; Premkumar B; Prabhawathi V; Prabhakar PK
    Mini Rev Med Chem; 2021; 21(20):3166-3182. PubMed ID: 33888049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.
    Sposito AC; Berwanger O; de Carvalho LSF; Saraiva JFK
    Cardiovasc Diabetol; 2018 Dec; 17(1):157. PubMed ID: 30545359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects.
    Zhao X; Wang M; Wen Z; Lu Z; Cui L; Fu C; Xue H; Liu Y; Zhang Y
    Front Endocrinol (Lausanne); 2021; 12():721135. PubMed ID: 34497589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control.
    Anagnostis P; Athyros VG; Adamidou F; Panagiotou A; Kita M; Karagiannis A; Mikhailidis DP
    Diabetes Obes Metab; 2011 Apr; 13(4):302-12. PubMed ID: 21205117
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
    Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
    Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GLP-1 receptor agonists and heart failure in diabetes.
    Scheen AJ
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S13-2S19. PubMed ID: 28431666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD.
    Patel Chavez C; Cusi K; Kadiyala S
    J Clin Endocrinol Metab; 2022 Jan; 107(1):29-38. PubMed ID: 34406410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.
    Bendotti G; Montefusco L; Lunati ME; Usuelli V; Pastore I; Lazzaroni E; Assi E; Seelam AJ; El Essawy B; Jang J; Loretelli C; D'Addio F; Berra C; Ben Nasr M; Zuccotti G; Fiorina P
    Pharmacol Res; 2022 Aug; 182():106320. PubMed ID: 35738455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.